Auf dieser Seite
HCWB HCW Biologics Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 14, 2026
$1,68
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$1,5052-Wochen-Tief
$29,2852-Wochen-Hoch
P/E (TTM)
-0.1
EPS (TTM)
$-13.98
Umsatz (TTM)
$7M
Ihre Abzeichen
52W-Spanne
$2–$29
Analystenbewertung
BUY
Kursziel
$30
P/E
-0.1
ROE
-151.4%
Nettogewinnmarge
-83.4%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
HCWB Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$1.68
P/E (TTM)
-0.1
EPS (TTM)
$-13.98
Umsatz (TTM)
$7M
ROE (TTM)
-151.4%
Verschuldungsgrad (MRQ)
0.9
52W-Spanne
$2–$29
HCWB Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 30. Juni 2026 | 1-for-6 | Umgekehrt |
| 11. April 2025 | 1-for-40 | Umgekehrt |
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$54.2K2020-12-31 → 2025-12-31
EPS$-10.632021-12-31 → 2025-12-31
Freier Cashflow$-13M2021-12-31 → 2025-12-31
Nettogewinnmarge-83.4%2022-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | HCWB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -0.15-Jahres-Durchschnitt ≈-77.5 | ≈-77.5 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | HCWB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Bruttogewinnmarge (TTM) | 96.3%5-Jahres-Durchschnitt ≈28.9% | ≈28.9% | · | · | |
| Betriebsgewinnmarge (TTM) | -114.5%5-Jahres-Durchschnitt ≈-6637.1% | ≈-6637.1% | -869.3% | Spitzenklasse | |
| EBITDA-Marge (TTM) | -105.5%5-Jahres-Durchschnitt ≈-6132.7% | ≈-6132.7% | -866.6% | Spitzenklasse | |
| Pretax Margin (Vorgewinnmarge) | -14677.1%5-Jahres-Durchschnitt ≈-4237.0% | ≈-4237.0% | · | · | |
| Nettogewinnmarge (TTM) | -83.4%5-Jahres-Durchschnitt ≈-4237.0% | ≈-4237.0% | -862.3% | Spitzenklasse | |
| ROA (TTM) | -20.1%5-Jahres-Durchschnitt ≈-49.6% | ≈-49.6% | -125.6% | Spitzenklasse | |
| ROE (TTM) | -151.4%5-Jahres-Durchschnitt ≈-72.5% | ≈-72.5% | -294.8% | Schwach | |
| ROIC | -137.5%5-Jahres-Durchschnitt ≈1572.2% | ≈1572.2% | · | · |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | HCWB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital (MRQ) | 0.95-Jahres-Durchschnitt ≈0.9 | ≈0.9 | 0.0 | Hohe Verschuldung | |
| Liquiditätsgrad (MRQ) | 0.15-Jahres-Durchschnitt ≈7.3 | ≈7.3 | 2.0 | Geringe Liquidität | |
| Quick Ratio (MRQ) | 0.05-Jahres-Durchschnitt ≈6.8 | ≈6.8 | 1.5 | Geringe Liquidität | |
| Interest Coverage (Zinsdeckungsgrad) | -15.65-Jahres-Durchschnitt ≈-68.0 | ≈-68.0 | · | · |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | HCWB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | -97.9%5-Jahres-Durchschnitt ≈-55.1% | ≈-55.1% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | -79.9% | · | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | -57.9% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | HCWB | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.05-Jahres-Durchschnitt ≈0.1 | ≈0.1 | 0.0 | Schwach | |
| Receivables Turnover (Forderungsumschlag) | 0.25-Jahres-Durchschnitt ≈9.0 | ≈9.0 | · | · | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$1.5K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-141.5%
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 14, 2026 | $-11.58 | $-2.02 | -473.4% |
| 31. März 2026 | Mai 14, 2026 | $2.22 | $-2.69 | 182.4% |
| 31. Dezember 2025 | $-18.36 | $-5.14 | -257.1% | |
| 30. September 2025 | $-12.12 | $-14.08 | 13.9% | |
| 30. Juni 2025 | $-6.48 | $11.02 | -158.8% | |
| 31. Dezember 2024 | $-3.20 | $3.67 | -187.1% | |
| 31. Dezember 2023 | $-12.00 | $-5.71 | -110.1% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $54.2K | $3M | $3M | $7M | $0 | $4M | |
| Cost of Revenue | $43.4K | $2M | $2M | $4M | $0 | · | |
| Gross Profit | $10.8K | $959.4K | $560.4K | $3M | $0 | · | |
| R&D Expense | $5M | $6M | $8M | $9M | $8M | $7M | |
| SG&A Expense | $8M | $7M | $7M | $8M | $5M | $3M | |
| Operating Expenses | $13M | $30M | $26M | $18M | $13M | $10M | |
| Operating Income | $-13M | $-29M | $-26M | $-15M | $-13M | $-6M | |
| Interest Expense | $845.1K | $654.3K | $283.0K | $126.7K | $0 | · | |
| Other Non-op | $0 | $-1M | · | · | · | · | |
| Pretax Income | $-8M | $-30M | $-25M | $-15M | $-13M | $-6M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-8M | $-30M | $-25M | $-15M | $-13M | $-6M | |
| EPS (Basic) | $-10.63 | $-30.96 | $-0.70 | $-0.42 | $-0.69 | · | |
| EPS (Diluted) | $-10.63 | $-30.96 | $-0.70 | $-0.42 | $-0.69 | · | |
| Shares (Basic) | 2,097,701 | 969,825 | 35,929,446 | 35,822,249 | 18,770,935 | · | |
| Shares (Diluted) | 2,097,701 | 969,825 | 35,929,446 | 35,822,249 | 18,770,935 | · | |
| EBITDA | $-12M | $-28M | $-25M | $-14M | $-13M | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2M | $5M | $4M | $22M | $12M | $8M | |
| Short-term Investments | $0 | $0 | $0 | $10M | $25M | · | |
| Receivables | $32.2K | $582.2K | $2M | $417.7K | $133.0K | $2M | |
| Prepaid Expense | $222.2K | $328.2K | $1M | $1M | $2M | $538.3K | |
| Other Current Assets | $77.6K | $113.5K | $230.9K | $196.0K | $1M | $654.5K | |
| Current Assets | $2M | $6M | $6M | $34M | $40M | $12M | |
| PP&E (Net) | $21M | $23M | $20M | $11M | $1M | $2M | |
| PP&E (Gross) | $25M | $27M | $23M | $13M | $3M | $3M | |
| Accum. Depreciation | $4M | $4M | $3M | $2M | $2M | $1M | |
| Other Non-current Assets | $28.5K | $28.5K | $56.5K | $333.9K | $393.3K | $34.2K | |
| Total Assets | $25M | $30M | $29M | $47M | $54M | $15M | |
| Accounts Payable | $13M | $22M | $6M | $1M | $223.7K | $155.3K | |
| Short-term Debt | $7M | $6M | $0 | · | · | · | |
| Current Liabilities | $21M | $30M | $9M | $3M | $2M | $1M | |
| Capital Leases | · | · | · | $14.3K | · | · | |
| Deferred Tax | $24.9K | $40.9K | $146.9K | $0 | · | · | |
| Other Non-current Liabilities | $692.5K | · | · | · | · | · | |
| Total Liabilities | $22M | $37M | $15M | $9M | $2M | · | |
| Long-term Debt | $0 | $7M | $6M | $6M | $0 | · | |
| Total Debt | $7M | $6M | $119.4K | $38M | · | · | |
| Common Stock | $55 | $111 | $3.6K | $3.6K | $3.6K | · | |
| Paid-in Capital | $111M | $94M | $84M | $83M | $82M | $0 | |
| Retained Earnings | $-109M | $-101M | $-71M | $-46M | $-31M | $-17M | |
| Stockholders' Equity | $3M | $-7M | $13M | $37M | $51M | $-17M | |
| Liabilities + Equity | $25M | $30M | $29M | $47M | $54M | $15M |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $1M | $717.9K | $543.6K | $572.9K | |
| Stock-based Comp | $768.6K | $1M | $1M | $1M | $361.0K | $21.9K | |
| Other Non-cash | $-7M | $14M | $341.2K | $3M | $982.2K | · | |
| Operating Cash Flow | $-13M | $-14M | $-23M | $-10M | $-11M | $-10M | |
| CapEx | $0 | $261.6K | $6M | $10M | $47.3K | $186.7K | |
| Investing Cash Flow | $0 | $-261.6K | $4M | $15M | $-35M | $-186.7K | |
| Debt Issued | · | · | · | · | $0 | $563.6K | |
| Net Debt Issued | · | · | · | · | $0 | · | |
| Stock Issued | $5M | $6M | $23.7K | $15.8K | $29.5K | $9.9K | |
| Net Stock Activity | $5M | $6M | $23.7K | $15.8K | $29.5K | · | |
| Financing Cash Flow | $11M | $16M | $-14.5K | $6M | $49M | $12M | |
| Net Change in Cash | $-3M | $1M | $-19M | $11M | $3M | $1M | |
| Free Cash Flow | $-13M | $-14M | $-29M | $-21M | $-11M | · | |
| Levered FCF | $-14M | $-15M | · | $-21M | · | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 20.0% | 37.4% | 19.7% | 38.5% | · | · | |
| Operating Margin | -24270.7% | -1148.5% | -905.0% | -224.3% | · | · | |
| Net Margin | -14677.1% | -1169.7% | -879.5% | -221.7% | · | · | |
| Pretax Margin | -14677.1% | -1169.7% | -879.5% | -221.7% | · | · | |
| EBITDA Margin | -22349.8% | -1102.4% | -865.0% | -213.6% | · | · | |
| ROA | -29.1% | -102.2% | · | -29.7% | -37.3% | · | |
| ROE | -586.8% | 358.7% | · | -37.3% | -24.4% | · | |
| ROIC | -137.5% | 6472.1% | · | -19.9% | -26.1% | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.1 | 0.2 | · | 11.5 | 17.4 | · | |
| Quick Ratio | 0.1 | 0.2 | · | 11.0 | 15.9 | · | |
| Debt / Equity | 2.5 | -0.9 | · | 1.0 | · | · | |
| Interest Coverage | -15.6 | -46.7 | -90.9 | -119.0 | · | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.1 | · | · | |
| Receivables Turnover | 0.2 | 2.4 | · | 24.4 | · | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue / Share | $0.03 | $0.07 | $0.08 | $0.19 | · | · | |
| Cash Flow / Share | $-6.38 | $-0.37 | $-0.63 | $-0.29 | · | · | |
| EPS (TTM) | $-10.63 | $-30.96 | $-0.70 | $-0.42 | $-0.69 | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue YoY | -97.9% | -9.7% | -57.7% | · | · | · | |
| Revenue CAGR 3Y | -79.9% | · | -11.5% | · | · | · | |
| Revenue CAGR 5Y | -57.9% | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue TTM | $54.2K | $3M | $3M | $7M | $0 | · | |
| Net Income TTM | $-8M | $-30M | $-25M | $-15M | $-13M | · | |
| P/E | -0.1 | -0.6 | -70.0 | -182.4 | -134.5 | · | |
| Earnings Yield | -1094.8% | -173.5% | -1.4% | -0.55% | -0.74% | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $151.7K | $6M | $27.0K | $15.6K | $6.5K | $5.1K | $394.8K | $426.4K | $618.9K | $1M | $1M | $853.1K | $622.8K | $41.9K | $1M | $2M | |
| Cost of Revenue | $229.5K | $11.1K | $21.6K | $12.5K | $5.2K | $4.1K | $315.8K | $341.1K | $438.4K | $512.0K | $1M | $678.3K | $502.4K | $29.4K | $1M | $1M | |
| Gross Profit | $-93.9K | $7M | $5.4K | $3.1K | $1.3K | $1.0K | $79.0K | $85.3K | $180.4K | $614.7K | $252.6K | $174.8K | $120.4K | $12.5K | $268.3K | $361.8K | |
| R&D Expense | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | |
| SG&A Expense | $2M | $2M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $564.4K | $2M | $2M | $3M | $3M | $2M | |
| Operating Expenses | $3M | $3M | $4M | $3M | $3M | $2M | $3M | $4M | $15M | $8M | $11M | $5M | $5M | $5M | $6M | $4M | |
| Operating Income | $-3M | $3M | $-4M | $-3M | $-3M | $-2M | $-3M | $-4M | $-15M | $-7M | $-11M | $-5M | $-5M | $-5M | $-6M | $-4M | |
| Interest Expense | $100.5K | $109.3K | $233.4K | $127.1K | $228.7K | $255.8K | $265.6K | $229.1K | $159.7K | $0 | $-1.4K | $95.5K | $95.5K | $93.4K | $94.5K | $32.2K | |
| Other Non-op | · | · | $0 | $0 | $0 | · | $0 | $0 | $-1M | · | · | $0 | $0 | · | · | · | |
| Pretax Income | $-5M | $4M | · | · | $-2M | $-2M | · | · | · | · | · | · | · | · | · | · | |
| Income Tax | · | $330.2K | $0 | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-5M | $3M | $719.2K | $-5M | $-2M | $-2M | $-3M | $-4M | $-15M | $-7M | $-11M | $-5M | $-4M | $-5M | $-5M | $-4M | |
| EPS (Basic) | $-11.58 | $1.39 | $-1.77 | $-2.02 | $-40.72 | $-11.80 | $-10.47 | $-4.13 | $-16.16 | $-0.20 | $-0.30 | $-0.14 | $-0.12 | $-0.14 | $-0.15 | $-0.11 | |
| EPS (Diluted) | $-11.58 | $1.39 | $-1.77 | $-2.02 | $-40.72 | $-11.80 | $-10.47 | $-4.13 | $-16.16 | $-0.20 | $-0.30 | $-0.14 | $-0.12 | $-0.14 | $-0.15 | $-0.11 | |
| Shares (Basic) | 1,327,966 | 904,312 | · | 2,260,068 | 296,686 | 186,149 | · | 945,585 | 945,585 | 37,223,588 | · | 35,926,921 | 35,910,669 | 35,883,779 | · | 35,835,135 | |
| Shares (Diluted) | 1,327,966 | 904,312 | · | 2,260,068 | 296,686 | 186,149 | · | 945,585 | 945,585 | 37,223,588 | · | 35,926,921 | 35,910,669 | 35,883,779 | · | 35,835,135 | |
| EBITDA | $-3M | $3M | · | $-3M | $-3M | $-2M | · | $-4M | $-15M | $-7M | · | $-5M | $-5M | $-5M | · | $-4M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $741.3K | $1M | $2M | $1M | $2M | $1M | $5M | $998.2K | $1M | $4M | $4M | $11M | $7M | $18M | $22M | $26M | |
| Short-term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | · | · | $0 | · | $0 | $10M | $10M | $10M | $0 | |
| Receivables | $18.5K | $74.8K | $32.2K | $30.7K | $21.6K | $87.5K | $582.2K | $651.8K | $655.0K | $903.9K | $2M | $710.1K | $707.2K | $252.7K | $417.7K | $355.6K | |
| Prepaid Expense | $282.5K | $297.8K | $222.2K | $210.7K | $295.5K | $256.3K | $328.2K | $356.2K | $404.9K | $783.4K | $1M | $2M | $1M | $1M | $1M | $2M | |
| Other Current Assets | $97.7K | $119.8K | $77.6K | $250.3K | $141.0K | $443.3K | $113.5K | $88.1K | $164.6K | $187.3K | $230.9K | $174.9K | $327.1K | $317.0K | $196.0K | $205.9K | |
| Current Assets | $1M | $2M | $2M | $2M | $3M | $2M | $6M | $2M | $2M | $6M | $6M | $14M | $20M | $30M | $34M | $29M | |
| PP&E (Net) | $21M | $21M | $21M | $23M | $23M | $23M | $23M | $23M | $23M | $23M | $20M | $15M | $13M | $12M | $11M | $11M | |
| PP&E (Gross) | · | · | $25M | · | · | · | $27M | · | · | · | $23M | · | · | · | $13M | · | |
| Accum. Depreciation | · | · | $4M | · | · | · | $4M | · | · | · | $3M | · | · | · | $2M | · | |
| Other Non-current Assets | $28.5K | $28.5K | $28.5K | $28.5K | $28.5K | $28.5K | $28.5K | $28.5K | $28.5K | $28.5K | $56.5K | $137.6K | $211.0K | $253.1K | $333.9K | $419.0K | |
| Total Assets | $27M | $27M | $25M | $25M | $29M | $26M | $30M | $27M | $27M | $30M | $29M | $36M | $39M | $44M | $47M | $51M | |
| Accounts Payable | $11M | $12M | $13M | $19M | $19M | $20M | $22M | $23M | $17M | $10M | $6M | $3M | $2M | $1M | $1M | $1M | |
| Short-term Debt | $7M | $7M | $7M | $7M | $6M | $6M | $6M | $6M | · | · | $0 | · | · | · | · | · | |
| Current Liabilities | $19M | $20M | $21M | $27M | $27M | $27M | $30M | $30M | $23M | $13M | $9M | $5M | $5M | $5M | $3M | $2M | |
| Capital Leases | · | · | · | · | · | · | · | · | · | · | · | · | · | $7.5K | · | $56.7K | |
| Deferred Tax | · | · | $24.9K | · | · | · | $40.9K | · | · | · | $146.9K | · | · | · | $0 | · | |
| Other Non-current Liabilities | · | $692.5K | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Liabilities | $19M | $22M | $22M | $28M | $29M | $35M | $37M | $37M | $33M | $22M | $15M | $12M | $11M | $11M | $9M | $9M | |
| Long-term Debt | · | · | $0 | $0 | $367.2K | $8M | $7M | $6M | $10M | $8M | $6M | $6M | $6M | $6M | $6M | $6M | |
| Total Debt | $7M | $7M | · | $7M | $6M | $6M | · | $6M | · | · | · | $117.7K | $97.1K | $68.0K | · | · | |
| Common Stock | $161 | $112 | $328 | $262 | $215 | $4.5K | $111 | $3.8K | $3.8K | $3.8K | $3.6K | $3.6K | $3.6K | $3.6K | $3.6K | $3.6K | |
| Paid-in Capital | · | · | $111M | $107M | $105M | $94M | $94M | $87M | $87M | $87M | $84M | $84M | $83M | $83M | $83M | $83M | |
| Retained Earnings | $-110M | $-105M | $-109M | $-109M | $-105M | $-103M | $-101M | $-97M | $-93M | $-78M | $-71M | $-60M | $-55M | $-51M | $-46M | $-40M | |
| Stockholders' Equity | $7M | $6M | $3M | $-2M | $-52.0K | $-9M | $-7M | $-10M | $-6M | $9M | $13M | $24M | $29M | $33M | $37M | $43M | |
| Liabilities + Equity | $27M | $27M | $25M | $25M | $29M | $26M | $30M | $27M | $27M | $30M | $29M | $36M | $39M | $44M | $47M | $51M |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $127.1K | $142.0K | $156.9K | $173.9K | $291.9K | $419.0K | $682.5K | $128.4K | $129.9K | $243.5K | $274.6K | $277.5K | $284.3K | $298.8K | $261.2K | $164.3K | |
| Stock-based Comp | $1.2K | $10.0K | $9.2K | $205.5K | $278.3K | $275.6K | $292.1K | $232.4K | $239.8K | $244.7K | $261.3K | $219.8K | $263.4K | $259.2K | $286.2K | $302.3K | |
| Other Non-cash | · | · | · | · | · | $-2M | · | · | · | $3M | · | · | · | $874.4K | · | · | |
| Operating Cash Flow | $-4M | $-2M | $-3M | $-3M | $-3M | $-4M | $-3M | $-3M | $-5M | $-4M | $-4M | $-6M | $-9M | $-4M | $-4M | $-2M | |
| CapEx | · | · | $0 | $0 | $0 | $0 | $113.4K | $37.1K | $-18.6K | $129.7K | $4M | $630.0K | $2M | $300.4K | $68.7K | $10M | |
| Investing Cash Flow | · | · | $0 | $0 | $0 | · | $-113.4K | $-37.1K | $18.6K | $-129.7K | $-4M | $9M | $-2M | $-300.4K | $-68.7K | $7M | |
| Stock Issued | · | · | $4M | $0 | $1M | $1.7K | $4M | $0 | $0 | $3M | $14.0K | $84 | $7.7K | $1.9K | $5.8K | $1.7K | |
| Net Stock Activity | · | · | · | · | · | $1.7K | · | · | · | $3M | · | · | · | $1.9K | · | · | |
| Financing Cash Flow | $3M | $851.6K | $4M | $2M | $5M | $-53.1K | $7M | $3M | $2M | $4M | $-15.2K | $-8.9K | $7.7K | $1.9K | $-39.8K | $6M | |
| Net Change in Cash | $-487.6K | $-723.6K | $855.6K | $-1M | $1M | $-4M | $4M | $-163.1K | $-3M | $489.0K | $-8M | $4M | $-11M | $-4M | $-4M | $11M | |
| Free Cash Flow | · | · | · | · | · | $-4M | · | · | · | $-4M | · | · | · | $-4M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | 100.5% | · | 20.0% | 20.0% | 20.0% | · | 20.0% | 29.1% | 54.6% | · | 20.5% | 19.3% | 29.9% | · | 20.0% | |
| Operating Margin | · | 49.8% | · | -21095.3% | -52886.7% | -38811.5% | · | -865.4% | -2445.8% | -665.1% | · | -595.2% | -724.2% | -12798.9% | · | -222.2% | |
| Net Margin | · | · | · | -29183.2% | -29431.0% | -43373.6% | · | -915.1% | -2469.1% | -662.8% | · | -578.9% | -691.1% | -12106.8% | · | -216.4% | |
| Pretax Margin | · | 58.5% | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | · | 52.0% | · | -21095.3% | -52886.7% | -30538.8% | · | -865.4% | -2445.8% | -643.5% | · | -595.2% | -724.2% | -12085.4% | · | -222.2% | |
| ROA | -18.8% | · | · | -17.5% | -6.9% | -7.8% | · | -12.6% | -46.1% | -20.2% | · | -11.4% | -9.9% | -10.7% | · | -7.3% | |
| ROE | -141.5% | · | · | 75.4% | 60.7% | -2460.8% | · | -56.2% | -137.1% | -36.1% | · | -14.9% | -11.5% | -12.4% | · | -8.1% | |
| ROIC | · | 23.9% | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.5 | · | 2.6 | 4.4 | 6.6 | · | 12.5 | |
| Quick Ratio | 0.0 | 0.1 | · | 0.0 | 0.1 | 0.0 | · | 0.1 | 0.1 | 0.4 | · | 2.2 | 4.0 | 6.3 | · | 11.6 | |
| Debt / Equity | 0.9 | 1.1 | · | -3.2 | -123.6 | -0.7 | · | -0.6 | · | · | · | 0.0 | 0.0 | 0.0 | · | · | |
| Interest Coverage | -31.5 | 29.6 | · | -25.9 | -15.1 | -7.7 | · | -16.5 | -94.8 | · | · | -53.2 | -47.2 | -57.4 | · | · |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.2 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | 80.1 | · | 0.0 | 0.0 | 0.0 | · | 0.6 | 0.9 | 1.9 | · | 1.6 | 1.2 | 0.1 | · | 8.5 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | · | $7.19 | · | $0.01 | $0.00 | $0.00 | · | $0.01 | $0.02 | $0.03 | · | $0.02 | $0.02 | $0.00 | · | $0.05 | |
| Cash Flow / Share | · | $-1.74 | · | · | · | $-0.08 | · | · | · | $-0.10 | · | · | · | $-0.10 | · | · | |
| EPS (TTM) | $-13.98 | $-43.12 | · | $-65.01 | $-67.12 | $-42.56 | · | $-20.79 | $-16.80 | $-0.76 | · | $-0.55 | $-0.52 | $-0.50 | · | $-0.22 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $7M | $7M | · | $422.0K | $832.8K | $1M | · | $3M | $4M | $4M | · | $3M | $4M | $4M | · | $5M | |
| Net Income TTM | $-6M | $-2M | · | $-12M | $-11M | $-25M | · | $-37M | $-38M | $-27M | · | $-20M | $-19M | $-18M | · | $-13M | |
| P/E | -0.4 | -0.1 | · | -0.3 | -0.4 | -1.6 | · | -6.2 | -9.2 | -552.6 | · | -829.1 | -1001.5 | -672.5 | · | -2498.2 | |
| Earnings Yield | -280.2% | -1996.3% | · | -292.8% | -282.1% | -62.9% | · | -16.1% | -10.8% | -0.18% | · | -0.12% | -0.10% | -0.15% | · | -0.04% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $54.2K | $3M | $3M | $7M | $0 |
| Bruttogewinnmarge % | 20.0% | 37.4% | 19.7% | 38.5% | · |
| Betriebsgewinnmarge % | -24270.7% | -1148.5% | -905.0% | -224.3% | · |
| Nettoergebnis | $-8M | $-30M | $-25M | $-15M | $-13M |
| Verwässerte EPS | $-10.63 | $-30.96 | $-0.70 | $-0.42 | $-0.69 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | 2.5 | -0.9 | · | 1.0 | · |
| Liquiditätsgrad | 0.1 | 0.2 | · | 11.5 | 17.4 |
| Quick Ratio | 0.1 | 0.2 | · | 11.0 | 15.9 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-13M | $-14M | $-29M | $-21M | $-11M |
Institutionelle Eigentümer (13F) 1 Einreicher · $15K gesamt · Stand 31. Dezember 2025
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
1
Gehaltener Wert
$15K
Neue Positionen
7
Geschlossene Positionen
4
Institutionelle Aktivität — Q1 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 7 (+2 vs. Vorquartal) | 4 (+3 vs. Vorquartal) | 5 (+2 vs. Vorquartal) | 0 (-2 vs. Vorquartal) | +48K |
Verglichen mit Q4 2025. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $14.979 | 15.426 | 100,00% | Aktien |
Aktivisten & 5%+-Eigentümer 2 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Hing C. Wong, Ph.D. ×2 Einreichungen | 13. Juni 2025 | 23,38% | Änderung | · | SEC |
| Hing C. Wong (2) | 22. November 2024 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 10 Insider · 5 Führungskräfte · 5 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Hing C. Wong, Ph.D. | Chief Executive Officer | 29. Juli 2026 P | 125.845 | 2 | 0 | $219.313 |
| Rebecca Byam | Chief Financial Officer | 22. Mai 2026 P | 57.245 | 1 | 0 | $19.929 |
| Lee Flowers | SVP of Business Development | 29. Juli 2026 P | 8.691 | 1 | 0 | $19.959 |
| Peter Rhode | Title of the Officer: Chief Scientific Officer and Vice President of Clinical Operations. | 11. Dezember 2023 M | 77.500 | 0 | 0 | $0 |
| Jin-An Jiao | VP of Development | 31. Mai 2022 M | 45.141 | 0 | 0 | $0 |
| Scott T Garrett | Direktor | 29. Juli 2026 P | 41.644 | 2 | 0 | $269.069 |
| Gary M Winer | Direktor | 16. Mai 2025 P | 4.075 | 0 | 0 | $0 |
| Rick S. Greene | Direktor | 7. Mai 2025 P | 2.066 | 0 | 0 | $0 |
| Lisa M. Giles | Direktor | 14. Juni 2024 A | 35.815 | 0 | 0 | $0 |
| Medmira Capital Ltd. | 10%-Eigentümer | 15. September 2021 J | 0 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 1 ETF
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | 0,00% | 2.004 SH | 19. August 2026 | Täglich |
HCWB Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 7 Analysten
KAUF
Median-Ziel
$30.00
+1685,7%
2 28,6%
Starker Kauf
4 57,1%
Kauf
1 14,3%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
1 Analysten · 2026-10-01Mittelwert-Ziel $30.00 +1685,7%
Tief$30.00
Mittelwert$30.00
Hoch$30.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| HCWB | · | -0.1 | -97.9% | -14677.1% | -586.8% | 20.0% |
| DRMA | · | · | · | · | · | · |
| PMCB | $8M | -0.3 | · | · | -56.7% | · |
| GRI | $122.9K | -0.0 | · | · | -256.3% | · |
| MBIO | · | -2.5 | · | · | -30.9% | · |
| BRTX | $10M | -0.7 | -10.3% | -3959.4% | -547.6% | 93.4% |
| GOVX | $296.2K | · | -37.1% | -862.3% | -645.9% | · |
| VIVS | $4M | -0.3 | -9.0% | -10567.2% | -294.8% | · |
| APVO | $9M | -0.1 | · | · | -217.2% | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 14, 2026